Health

ASDSA Applauds FDA for Safety Communication on Needle-less Injector Devices

Leave a comment


ASDSA Patient Safety Alert

ASDSA Patient Safety Alert on Hyaluron Pens

We urge consumers to see a board certified dermatologist before undertaking any cosmetic procedures to make sure all medical questions can be answered prior to treatment.


ROLLING MEADOWS, Ill. (PRWEB)

The American Society for Dermatologic Surgery Association (ASDSA) applauds the U.S. Food and Drug Administration (FDA) for sending out a safety communication regarding needle-less devices, such as hyaluron pens (HA pens) for injection of dermal fillers. ASDSA had earlier sounded the alarm on these devices and has resources available on these devices, including a downloadable flyer, and raised this issue with the FDA.

ASDSA members, board certified dermatologists, have found questionable social media videos in which children use these devices to self-inject and promote their use to peers. Consumers are told that these devices can create lift and fill lips, nasolabial lines, marionette lines, 11 lines and forehead wrinkles. However, the FDA recommends not using these devices; buying or using lip or dermal fillers sold directly to the public; and injecting oneself or others with any filler (FDA-approved dermal fillers are indicated for prescription use only).

“I am pleased that the FDA has taken notice of this disturbing new trend, especially that of children using these devices on social media. We urge consumers to see a board certified dermatologist before undertaking any cosmetic procedures to make sure all medical questions can be answered prior to treatment,” said ASDSA President Mathew Avram, MD, JD. “The complexity of facial anatomy requires in-depth knowledge and expertise, and patients should always have medical procedures done by a physician who also has knowledge of adverse events.”

ASDSA urges its members to report adverse event to the CAPER Registry, a partnership between ASDSA and Northwestern University’s Department of Dermatology. ASDSA members should also report applicable events to MedWatch, the FDA Safety Information and Adverse Event Reporting program.

ASDSA’s top priority is patient safety and the FDA’s safety communication on these devices will help ensure consumers know the risks of self-injecting fillers. Contact advocacy@asds.net if you have questions.

###

About ASDSA

With a membership of 6,400+ physicians, ASDSA is a 501(c) (6) association, dedicated to education and advocacy on behalf of dermatologic surgeons and their patients. For more information, visit http://asds.net/ASDSA

Follow @ASDSAdvocacy on Facebook, Twitter, Instagram and LinkedIn!

Share article on social media or email:



Leave a Reply